{"id":576,"date":"2026-08-06T16:26:23","date_gmt":"2026-08-06T16:26:23","guid":{"rendered":"https:\/\/www.merckconnect.com\/idvynso\/?page_id=576"},"modified":"2026-08-20T08:44:50","modified_gmt":"2026-08-20T08:44:50","slug":"discontinuation-rate","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/","title":{"rendered":"Discontinuations rate"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
<\/div>\"\"<\/picture>

Adverse events leading to discontinuation by week 48<\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\n

Adverse events leading to discontinuation by week 48 in Trials 052 and 051<\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

The safety assessment of IDVYNSO in virologically-suppressed (HIV-1 RNA < 50 copies\/mL) PLWH was based on week 48 data from two phase 3, randomized trials, Trial 052 and Trial 051.<\/p>\n\n\n\n

<\/div>\n\n\n\n

A total of 708 participants received once-daily IDVYNSO.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Adverse Events (AEs) Leading to Discontinuation by Week 48<\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/th>Trial 052 (N=513; double-blinded)<\/span><\/th> Trial 051 (N=551; open-label)<\/span><\/th><\/tr>
Outcome<\/span><\/th>IDVYNSO<\/span> (n=342)<\/span><\/th>BIC\/FTC\/TAF (n=171)<\/span><\/strong><\/th>IDVYNSO<\/span> (n=366)<\/span><\/th>Baseline ART (n=185)<\/span><\/strong><\/td><\/tr>
AEs leading to discontinuation<\/th>3%<\/strong><\/td>2%<\/strong><\/td>0.5%<\/strong><\/td>2%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div>\n\n\n
Among Participants Callout DKTP<\/title><\/path><\/path><\/svg> <\/div><\/div>
Among Participants Callout DKTP<\/title><\/path><\/path><\/svg> <\/div><\/div>
<\/path><\/path><\/svg> <\/div><\/div><\/div>\n\n\n
<\/div>\n\n\n\n\n
\n\n\n\n
<\/div>\n\n\n\n

Continue exploring Trials 052 and 051<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

View adverse reaction data ><\/a><\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n

Abbreviations<\/strong><\/h4><\/div>\n\n\n\n
<\/div>\n\n\n\n

ART, antiretroviral therapy; BIC, bictegravir; FTC, emtricitabine; PLWH, people living with HIV; RNA, ribonucleic acid; TAF, tenofovir alafenamide.<\/p>\n\n\n\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The safety assessment of IDVYNSO in virologically-suppressed (HIV-1 RNA < 50 copies\/mL) PLWH was based on week 48 data from two phase…<\/p>\n","protected":false},"author":4249,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[247],"ga4_page_birn_id":[],"ga4_page_branding":[264],"ga4_page_businessunit":[],"ga4_page_campaign":[],"ga4_page_content_purpose":[280],"ga4_page_customer_journey_stage":[341],"ga4_page_customer_specialty":[366],"ga4_page_experience":[],"ga4_page_indication":[471],"ga4_page_material_intent":[563],"ga4_page_product":[616],"ga4_page_region":[793],"ga4_page_therapeuticarea":[839],"user_role":[],"mhh-area-of-interest":[],"access":[],"user_status":[],"class_list":["post-576","page","type-page","status-publish"],"yoast_head":"\nDiscontinuation Rate for IDVYNSO\u2122 (doravirine\/islatravir)<\/title>\n<meta name=\"description\" content=\"Review adverse event data leading to discontinuation of IDVYNSO\u2122 (doravirine\/islatravir) observed in Trial 052 and Trial 051.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Discontinuation Rate for IDVYNSO\u2122 (doravirine\/islatravir)\" \/>\n<meta property=\"og:description\" content=\"Review adverse event data leading to discontinuation of IDVYNSO\u2122 (doravirine\/islatravir) observed in Trial 052 and Trial 051.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/\" \/>\n<meta property=\"og:site_name\" content=\"tradename-mc\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T08:44:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk.png?w=1232\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Discontinuation Rate for IDVYNSO\u2122 (doravirine\/islatravir)","description":"Review adverse event data leading to discontinuation of IDVYNSO\u2122 (doravirine\/islatravir) observed in Trial 052 and Trial 051.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/","og_locale":"en_US","og_type":"article","og_title":"Discontinuation Rate for IDVYNSO\u2122 (doravirine\/islatravir)","og_description":"Review adverse event data leading to discontinuation of IDVYNSO\u2122 (doravirine\/islatravir) observed in Trial 052 and Trial 051.","og_url":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/","og_site_name":"tradename-mc","article_modified_time":"2026-08-20T08:44:50+00:00","og_image":[{"url":"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk.png?w=1232","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/","url":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/","name":"Discontinuation Rate for IDVYNSO\u2122 (doravirine\/islatravir)","isPartOf":{"@id":"https:\/\/www.merckconnect.com\/idvynso\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/#primaryimage"},"image":{"@id":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk.png?w=1232","datePublished":"2026-08-06T16:26:23+00:00","dateModified":"2026-08-20T08:44:50+00:00","description":"Review adverse event data leading to discontinuation of IDVYNSO\u2122 (doravirine\/islatravir) observed in Trial 052 and Trial 051.","breadcrumb":{"@id":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/#primaryimage","url":"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk.png","contentUrl":"https:\/\/www.merckconnect.com\/idvynso\/wp-content\/uploads\/sites\/338\/2026\/08\/Full-Overlay-desk.png","width":1128,"height":218},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.com\/idvynso\/discontinuation-rate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.com\/idvynso\/"},{"@type":"ListItem","position":2,"name":"Discontinuations rate"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.com\/idvynso\/#website","url":"https:\/\/www.merckconnect.com\/idvynso\/","name":"tradename-mc","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.com\/idvynso\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/pages\/576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/users\/4249"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/comments?post=576"}],"version-history":[{"count":7,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/pages\/576\/revisions"}],"predecessor-version":[{"id":864,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/pages\/576\/revisions\/864"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/media?parent=576"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_audience?post=576"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_birn_id?post=576"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_branding?post=576"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_businessunit?post=576"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_campaign?post=576"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=576"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=576"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=576"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_experience?post=576"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_indication?post=576"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_material_intent?post=576"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_product?post=576"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_region?post=576"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=576"},{"taxonomy":"user_role","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/user_role?post=576"},{"taxonomy":"mhh-area-of-interest","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/mhh-area-of-interest?post=576"},{"taxonomy":"access","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/access?post=576"},{"taxonomy":"user_status","embeddable":true,"href":"https:\/\/www.merckconnect.com\/idvynso\/wp-json\/wp\/v2\/user_status?post=576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}